| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.094 | 0.001 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |